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Abstract
Objectives: To determine the frequency of metabolic syndrome in type 2 diabetes according to three commonly
used operational definitions {World Health Organization(WHO), National Cholesterol Education Program Adult
Treatment Panel( NCEP ATP III) and International Diabetes Federation( IDF)}. To evaluate the agreement
between these classifications in the Pakistani cohort.
Methods: Data was collected retrospectively of 210 patients with type 2 diabetes visiting outpatient clinics of one
of the large tertiary care hospitals at Karachi, Pakistan between June 2008 to November 2008.
Results: The prevalence of metabolic syndrome was found to be 81.4% (WHO), 86.7 %( IDF) and 91.9 %(
NCEP ATPIII). The degree of agreement (kappa statistic) was found to be highest among IDF & NCEP ATPIII
(0.728) as compared to (0.436 & 0.417) between WHO & ATP and WHO & IDF respectively. The most significant
predictors for metabolic syndrome were found out to be female gender OR= 8.74 95% CI 1.51-50.53, low HDL
cholesterol levels OR= 0.89 95% CI 0.84-0.94 and high systolic blood pressure OR= 1.06 95% CI 1.009-1.11.
Conclusion: Our study results suggested that NCEP ATPIII and IDF are the most reliable criteria for diagnosing
metabolic syndrome in type 2 diabetic patients, with NECP capturing more patients in comparison to IDF
definition. The alarmingly high frequency of metabolic syndrome in type 2 diabetes found in this study suggests
that primary prevention strategies should be initiated earlier and early in this ethnic group and our health care
system should be geared up to cope with this deadly quartet.
Keywords: Diabetes, Metabolic Syndrome, Obesity, Prevalence World Health Organization (JPMA 62: 569; 2012).
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Introduction
Rapid urbanization, modernization and population
growth in developing countries has led to an upsurge of noncommunicable diseases1 associated with significant
morbidity and mortality along with certain cancers.2
Metabolic Syndrome (MS) also described as "Deadly
Quartet" and X syndrome3,4 is one of these disease entities
defined by cluster of cardiovascular risk factors which to a
greater extent is influenced by ethnicity/race. This
encompasses atherogenic dyslipidaemia, hypertension,
dysglycaemia and visceral obesity and pro coagulant state.5
Apart from increasing prevalence, the age of onset is also
declining among South Asian (SA) population6 due to genetic
predisposition and consumption of easily available energy
dense foods from an early age. This trend has got major
health implications since South Asians constitute one fifth of
world's population7 and the health care system in majority of
these countries is not very primed to deal with these medical
conditions.
Five diagnostic criteria have been put forward since
the inception of this syndrome MS which has created
perplexity among practitioners. In 1998, World Health
Organization (WHO) initially proposed a definition for MS
metabolic syndrome8 with main emphasis on gluco-centricity
(Table-1). In 1999, the European Group for the study of
Insulin Resistance (EGIR) recommended more or less similar
criteria with lower cut offs for hypertension.9

weight to each component of metabolic syndrome MS as
compared to IDF for which abdominal obesity remains a
prerequisite
for
the
diagnosis.13
Moreover,
microalbuminuria which is a controversial variable of
WHO criteria is not included in other definitions. Among
these definitions, WHO, NCEP ATPIII & IDF have been
the main ones which are used most widely.
Type 2 diabetes is also emerging as a global epidemic
with increasing prevalence in developing countries.14
Pakistan is among top ten countries estimated to have the
highest number of diabetics occupying sixth position on the
diabetes prevalence listing currently15,16 and it is estimated
that prevalence would be doubled by 2025. MS Metabolic
syndrome in combination with diabetes increases the risk of
both macro vascular, micro vascular complications and
atherosclerosis progression due to associated hypertension,
lipoprotein abnormalities and visceral obesity.17
There are studies that have looked into the differences
in most widely used definitions of metabolic syndrome MS in
general,18-21 but only few studies have compared these
definitions in the diabetic population.22-24 Therefore we
decided to determine the frequency of MS metabolic
syndrome in Type 2 diabetics according to NCEP ATPIII, IDF
and WHO definitions and then to compare these traits within
the Pakistani population.

Methods

Thereafter in 2001, NCEP ATP III National
Cholesterol Education Program Adult Treatment Panel III
(NCEP ATP III) proposed another definition for the diagnosis
of metabolic syndrome MS with less focus on insulin
resistance as compared to WHO criteria but not addressing
separate cut off points of waist circumference for Asian
population initially.10 In 2003, American Association of
Clinical Endocrinologists (AACE) proposed another set of
criteria for the diagnosis of MS metabolic syndrome. The
main limitation of the above mentioned criteria is that the
diagnosis is based on clinical judgment instead of presence of
specific number of risk factors.11

This cross-sectional study was conducted in the outpatient clinics at a tertiary care hospital of Karachi, Pakistan.
Data of 210 type 2 diabetes patients was collected
retrospectively who were visiting the clinics between June
and November 2008, by using a questionnaire which
included demographic characteristics and individual
components of MS i.e. weight, height, waist circumference
and BMI etc. Both hip and waist circumference were
recorded in centimeters and waist/hip ratio was calculated
(WHR). BMI was calculated as a ratio of weight in kg to
height in meters squared. Data was compiled between June
and August 2009.

Considering that SA have a higher percentage of
body fat mainly in the form of abdominal adiposity at a
lower Body Mass Index (BMI) in comparison with other
population,12 International Diabetes Federation (IDF) in
2005 suggested separate cutoff points of waist
circumference for Asian population and defined central
obesity as waist circumference of more than 80 cm for
women and 90 cm in men based on local statistics from the
corresponding area.13 The revised NCEP ATPIII modified
for SA South Asian population incorporated the same cut
off points for Asian population as given by IDF. Apart
from the cut off differences, NCEP ATP III gives equal

The sample size was calculated on an assumption that
minimum 208 participants would be required to study the
frequency of (MS) metabolic syndrome in type 2 diabetics of
around 46-74% (2, 25) to achieve 80% power, 0.068
percentage point of true value and 5% significance level.
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The laboratory tests which are routinely done for
patients with type 2 diabetes including triglycerides and high
density lipoprotein (HDL-C) were recorded. Patients already
on anti-hypertensive and anti-lipid medications specifically
in the form of fibric acid derivatives and niacin were taken as
cases of hypertension and hypertriglyceridaemia respectively,
irrespective of their blood pressure and lipid levels.
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The data was analyzed separately according to NCEP
ATP III, IDF and WHO definitions and the results were then
compared. The frequency of MS was calculated with 95% CI
based on three different criteria's. The data were presented as
the mean ± SD and median [inter-quartile range (IQR)] for
skewed variables, respectively. Categorical variables were
presented as numbers and percentages; Continuous variables
were compared using Student t test for normally distributed
variables and Wilcoxon rank-sum test for non-normally
distributed variables and categorical variables were compared
by chi-square or Fisher exact test. All analyses were
conducted by using the statistical package for social sciences
SPSS 14. A kappa test was done to determine the concurrence
between three definitions. In univariate analysis, comparison
between MS and without MS was done for each variable of
interest. Multivariable logistic regression analysis was
conducted to identify the factors associated with MS. All p
values were two tailed and considered statistically significant
if < 0.05.

Results
Description of baseline, anthropometric and
laboratory parameters of type 2 diabetics comparing patients
fulfilling any one of the three definitions of metabolic
syndrome MS with those not having MS syndrome are
provided in Table-2.
Out of total 210 type 2 diabetic patients, 112 (53.3%)
were males and 98 (46.7%) were females. Their mean age
was 53.67 ± 11.17 years (Table-2). The mean duration of
diabetes mellitus was 8.48 ± 7.18 years. Total 193 (91.9%)
were found to have metabolic syndrome according to NCEP
ATP III in comparison to 182 (86.7%) based on IDF criteria.

Figure-1: Frequency of Metabolic Syndrome according to three main diagnostic
criteria.

Lower frequency was documented with WHO criteria of 171
(81.4%) Figure-1. The frequency increased to 179 (85.2%) by
WHO, using the new cut offs for defining overweight (BMI
of 23 vs. 30).
The degree of agreement (kappa statistic) between
WHO, ATP III and WHO, IDF definitions were 0.436 95% CI
0.26-0.60 and 0.417 95%CI 0.25-0.57respectively. In contrast
kappa statistic between IDF and ATP III definitions was
found to be 0.728 95%CI 0.57-0.87.The overall agreement
between three definitions was 0.37 (95% CI 0.26-0.51)
Figure-2.
Central obesity was present in 162 (77%) patients by
WHO criteria followed by 197 (90.5%) based on IDF and
NCEP ATP III. Hypertension was found in 116 (55.2%)
patients according to WHO in comparison to 147 (70%) by
NCEP & IDF cut off of blood pressure. Presence of low HDL

Table-1: Diagnostic Criteria for the Metabolic Syndrome from WHO, NCEP (ATPIII) and IDF definitions.
WHO

NCEP(ATPIII)

IDF

Diabetes or impaired glucose or insulin
resistance (obligatory) plus two or more of
the following
Obesity: BMI > 30kg/m² or WHR >0.9
(M) >0.85 (F)

Any three of the five criteria below constitute a
diagnosis of Metabolic Syndrome
Central Obesity * (Waist circumference ethnicity
specific. For South Asians >90 cm in Men
>80 cm in women

Central Obesity (pre requisite) plus any two of the four
other criteria constitute a diagnosis of Metabolic Syndrome
Central Obesity * (Waist circumference ethnicity specific.
For South Asians >90 cm in Men
>80 cm in women

Dyslipidaemia:
Triglycerides >150 mg/dl (1.7mmol/l)

Dyslipidaemia:
Raised Triglycerides >150mg/dl (1.7mmol/l)
Or on specific treatment for this lipid disorder.

Dyslipidaemia:
Raised Triglycerides >150mg/dl (1.7mmol/l)
Or on specific treatment for this lipid disorder.

Reduced HDL-C < 35 mg/dl (0.9mmol/l)
(M) < 39mg/dl (1.0mmol/l) (F)
or on specific treatment for this lipid
disorder
Hypertension: Blood Pressure > 140/90
mm Hg or medication

Reduced HDL <40mg/dl (1.03mmol/l) in M
<50mg/dl (1.29 mmol/l) in Women
Or on specific treatment for this lipid disorder.

Reduced HDL <40mg/dl (1.03mmol/l) in M <50mg/dl
(1.29 mmol/l) in Women
Or on specific treatment for this lipid disorder.

Hypertension: Blood Pressure >130 Systolic >85
diastolic or on treatment for hypertension

Hypertension: Blood Pressure >130 Systolic >85 diastolic
or on treatment for hypertension

Microalbuminuria: Albumin excretion > 20
µg/min or albumin: creatinine ratio > 30mg/g

Raised Fasting Glucose >100 mg/dl (5.6mmol/l)
or previously diagnosed type 2 diabetes

Raised Fasting Glucose >100 mg/dl (5.6mmol/l) or
previously diagnosed type 2 diabetes
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Table-2: Basic anthropometric and Laboratory Characteristics of Patients with Type 2 Diabetes with and without MS Metabolic Syndrome.

Age, years
Sex
Male
Female
BMI kg/m2, median (IQR)
Waist circumference
Triglycerides (mg/dl), median (IQR)
HDL cholesterol (mg/dl), median (IQR)
Blood Pressure (mmHg)
Systolic B.P
Diastolic B.P
Microalbuminuria, median (IQR)

Patients with Metabolic
Syndrome N=196

Patients without Metabolic
Syndrome N=14

P value

53.67 ± 11.17

48.86 ± 14.64

0.12
0.050

101(51.5)
95(48.5)
26.60 (6.57)
100.69 ± 10.44
137 (87.5)
39 (13)

11(78.6)
3(21.4)
24.76 (7)
93.67 ± 8.55
109 (55.25)
48.50 (18)

0.10
0.01
0.005
<0.001

126.62 ± 17.46
76.07 ± 10.11
8.34 (21)

113.57 ± 8.41
72.14 ± 8.01
4.57 (8.13)

<0.001
0.15
0.06

Data shown as mean ± SD (Standard Deviation)
Gender distribution is shown as no & percentages.

Table-3: Frequency of 95% CI of MS Metabolic Syndrome using
WHO, NCEP (ATPIII) and IDF Criteria by Age and Gender.
n

WHO n (%)

ATPIII n (%)

IDF n (%)

Total

210

171 (81.4)
(75.61-86.09)

193 (91.9)
(87.41-94.86)

182 (86.7)
(81.3-90.59)

Male
< 45

32

46-55

36

56-65

25

> 66

19

Total

112

24 (75)
(57.74-86.70)
29 (80.55)
(64.84-90.17)
19 (76)
(56.35-88.42)
15 (78.94)
(56.33-91.34)
87 (77.67)
(69.09-84.38)

28 (87.5)
(71.79-94.89)
32 (88.88)
(74.58-95.46)
22 (88)
(69.84-95.64)
17 (89.47)
(68.30-96.79)
99 (88.39)
(81.13-93.05)

23 (71.87)
(54.47-84.40)
31 (86.11)
(71.22-93.80)
19 (76)
(56.35-91.34)
15 (78.94)
(56.33-91.34)
88 (78.57)
(70.06-85.14)

Female
< 45

17

46-55

31

56-65

40

> 66

10

Total

98

13 (76.47)
(52.36-90.30)
25 (80.64)
(63.56-90.72)
37 (92.5)
(80.07-97.27)
9 (90)
(58.72-97.71)
84 (85.71)
(77.41-91.26)

17
(81.46-99.85)
29 (93.54)
(79.19-98.02)
38 (95)
(83.46-98.46)
10
(71.50-99.77)
94 (95.91)
(89.99-98.73)

17
(81.46-99.85)
29 (93.54)
(79.19-98.02)
38 (95)
(83.46-98.46)
10
(71.50-99.77)
94 (95.91)
(89.99-98.73)
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cholesterol again differed being present in 77 (36.7%) when
WHO definition was applied and 144 (68.6%) by ATP III and
IDF.

Odd ratio [95% CI)

Furthermore, gender wise breakdown of frequency of
MS by WHO showed that 84 (85.7%) females suffered from
MS as compared to 87 (77.7%) males, a difference not
statistically significant (p=0.13). However, by all other
criteria MS was significantly more common among females
as compared to males, 95.9% vs. 88.4% (p=0.04) by ATP III
and 95.9% vs. 78.6% (p<0.001) by IDF (Table-3).

1.0
8.74[1.51,50.53]
0.89[0.84,0.94]
1.06[1.009,1.11]

For prevalence of hypertriglyceridaemia, no
statistically significant difference between both genders were
found. However, for low HDL cholesterol, prevalence was
higher in males, 44 (57.14%) than in females 33 (43%) by
WHO criteria (p<0.001). In contrast on the basis of ATP III

Table-4: Risk factor predicting prevalence of metabolic syndrome.

Sex
Male
Female
HDL cholesterol (mg/dl)
Systolic B.P

Figure-2: Degree of agreement (kappa statistic) between three definitions of
Metabolic Syndrome.
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and IDF definitions, prevalence of low HDL cholesterol
levels were higher (p=0.009) in females 77(57.46%) than in
males 57(42.53%). Likewise, central obesity was found to be
more common among female patients based on IDF and
NCEP (ATPIII) cutoffs 64.8% females vs. 35.2% males
(<0.001) but showing reverse pattern with WHO criteria,
57.14% males vs. 43% females (p <0.001).
To find out the independent predictors of MS, a
multivariable logistic regression was performed. Female
gender, low HDL cholesterol and high systolic blood
pressure were found to be the most important predictors
for MS (Table-4).

Discussion
Our study showed a considerably high frequency of
MS in people with type 2 diabetes based on NECP (ATPIII)
and IDF criteria. The frequency was quite high in comparison
to 46-76% found in other hospital based studies from
Pakistan.25-27 This is very interesting keeping in view that all
of these studies were done in the same region. The disparity
could be attributed to lower frequency of obesity (30-74%)
found in the above mentioned studies in comparison to our
study (90.5%). It is speculated that this intra-regional
difference could be due to the fact that certain communities
have high tendency to develop obesity and MS despite of
belonging to the same region due to differences in life style,
eating habits and level of physical activity.28 On the other
hand, another hospital based study from Pakistan revealed
comparable frequency of MS according to NCEP criteria.29
One of the hospital based studies in Iran, showed the
prevalence of MS in type 2 diabetics according to the NCEP
(ATPIII) criteria, to be 65%.30 In this study instead of BMI,
waist circumference was used highlighting the importance of
abdominal adiposity, a better marker of MS as compared to
BMI. A multicenter hospital based study in Brazil and
Finland showed a close frequency of central obesity and MS
(85 & 91.5%) was observed in type 2 diabetics[31] although
the study population comprised of people of European
descent. Our data was also consistent with an Indian study
showing prevalence of 91.1% MS20 using the same NCEP
(ATPIII) definition. However, separate components of MS
were found to be more common in our population as
compared to South Indians.20 The higher frequency of MS in
diabetic population found in our study is a source of major
concern since diabetes itself is an important risk factor for
atherosclerotic cardiovascular disease (ASCVD) and the
presence of the components of the MS in type 2 diabetics are
associated with both micro and macro vascular complications
as well as distal neuropathy.31
All type 2 diabetic patients should therefore be
screened for MS and offered intensive management to avoid
573

complications as coronary heart disease which is closely
linked with central obesity and insulin resistance.32
The higher frequency of MS in women according to
all criteria is also consistent with other studies from South
Asian countries.33,34 This could be attributed to less physical
activity in women due to ethnic and cultural restrictions. This
also highlights the importance of education of our women in
terms of prevention of MS with life style changes which
would indirectly influence the eating habits of the whole
family.
Regarding the selection of criteria for diagnosing MS
the slightly higher prevalence of MS by ATP III definition in
comparison to IDF (91.9% vs. 86.7%) could be attributed to
the relative flexibility of the ATP III in which abdominal
obesity is not considered as a prerequisite for the diagnosis.
Except for this difference the ATP III and IDF
definitions are essentially identical as seen by the degree of
agreement (kappa statistic= -0.728). According to this, NCEP
(ATPIII) and IDF are the most reliable criteria's for
diagnosing MS in type 2 diabetic patients, with NECP
capturing more patients in comparison to IDF. In contrast
WHO showed lower frequency of MS due to different cutoffs
used for HDL levels and obesity. This difference remained
significant even after adjusting it with BMI cutoffs for Asian
population of 23 vs.30 endorsed by WHO expert
consultation35 pointing towards the fact that waist
circumference or central obesity is a more valuable tool for
detection of MS in Asian population.

Conclusion
On the basis of these findings NCEP (ATPIII)
modified criteria should preferably be used in the Pakistani
population. Using waist circumference an obligatory criterion
still missed out 5.2% cases of MS in our study. To further
validate these recommendations, more studies are required to
estimate the predictive power for micro and macro vascular
complications and to establish the most appropriate definition
of MS for South Asian population with type 2 diabetes. The
alarmingly high frequency of MS in type 2 diabetes found in
our study, indicates that our health care system should to take
emergent steps in implementing life style intervention
programmes.
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